Enlivex Therapeutics Ltd. Expected to Post FY2025 Earnings of ($0.55) Per Share (NASDAQ:ENLV)

Enlivex Therapeutics Ltd. (NASDAQ:ENLV) – HC Wainwright issued their FY2025 earnings estimates for shares of Enlivex Therapeutics in a research report issued to clients and investors on Friday, April 12th. HC Wainwright analyst R. Selvaraju forecasts that the company will post earnings per share of ($0.55) for the year. HC Wainwright currently has a “Buy” rating and a $7.00 target price on the stock. The consensus estimate for Enlivex Therapeutics’ current full-year earnings is ($0.86) per share.

Enlivex Therapeutics Price Performance

Shares of Enlivex Therapeutics stock opened at $1.58 on Monday. The company’s fifty day simple moving average is $3.46 and its 200-day simple moving average is $2.55. The stock has a market capitalization of $29.34 million, a PE ratio of -1.01 and a beta of 1.02. Enlivex Therapeutics has a 1-year low of $1.20 and a 1-year high of $4.59.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. UBS Group AG lifted its stake in shares of Enlivex Therapeutics by 73.4% during the 3rd quarter. UBS Group AG now owns 31,871 shares of the company’s stock valued at $136,000 after buying an additional 13,490 shares in the last quarter. Bank of America Corp DE lifted its stake in Enlivex Therapeutics by 87.0% in the 1st quarter. Bank of America Corp DE now owns 6,163 shares of the company’s stock worth $34,000 after purchasing an additional 2,867 shares in the last quarter. Jane Street Group LLC lifted its stake in Enlivex Therapeutics by 89.6% in the 1st quarter. Jane Street Group LLC now owns 52,507 shares of the company’s stock worth $294,000 after purchasing an additional 24,807 shares in the last quarter. Finally, Goldman Sachs Group Inc. purchased a new stake in Enlivex Therapeutics in the 1st quarter worth $68,000. Hedge funds and other institutional investors own 1.02% of the company’s stock.

About Enlivex Therapeutics

Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors.